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Background: The modification of stromal components with the disappearance of CD34 positive fibrocytes and by
contrast the acquisition of smooth-muscle actin positive myofibroblasts is a frequent event in breast carcinomas
but has been little studied in its metastatic sites. Therefore, the aim of the present study is to examine the stromal
expression of CD34 and SMA in lymph node and liver metastases which are two of the most frequent metastatic
breast cancer sites.
Methods: The distribution of CD34 fibrocytes and SMA myofibroblasts has been studied by immunohistochemistry
in 41 lymph node and 36 liver metastases from patients with invasive carcinoma of no special type.
Results: No CD 34 fibrocytes were noted in the stroma of metastasis. By contrast, smooth-muscle actin stromal
expression was observed in 95.1% of lymph node and 97.2% of liver metastases, independently of histological
features of tumours.
Conclusions: Myofibroblasts represent a major and constant component in the metastatic tumoral stroma of breast
carcinoma highlighting that these cells could play an active role in tumour cells proliferation and spread.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_196
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The importance of the stromal microenvironment has
been suggested to play a major role in breast carcinoma
by promoting tumour growth, progression and invasion
[1-4]. In particular according to these data we and others
have clearly demonstrated that the loss of CD34 fibro-
cytes and acquisition of peritumoral myofibroblasts ex-
pressing smooth muscle actin (SMA) is a fundamental
step both in ductal carcinoma in situ (DCIS) and invasive
carcinoma of no special type (NST) [5,6]. If the acquisi-
tion of a myofibroblastic differentiation is an important
data in peritumoral connective tissue remodeling [4], the
morphological characterization of stromal microenviron-
ment and particularly of myofibroblastic peritumoral cells* Correspondence: xavier.catteau06@gmail.com
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unless otherwise stated.in metastatic location is less understood. In preliminaries
studies, some authors have suggested that the acquisition
of a myofibroblastic differentiation could play a role in
metastatic colonic adenocarcinoma [7] but however, until
now, these data have not been clearly described in breast
metastatic sites. Therefore, to clarify this issue, the aim of
the present study is to assess by immunohistochemistry,
the topographic distribution of CD 34 positive fibrocytes
and SMA positive myofibroblasts both in axillary lymph
node and liver metastases which are frequent in breast
carcinoma and strongly associated with an increased risk
of distant metastasis and poor overall survival [8].Methods
Study population
We used a computer database from the Pathology and
Genetics Institute (IPG) to identify 77 consecutive patients
diagnosed between January 2008 and December 2012 withl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 2 Antibodies used in this study
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http://www.diagnosticpathology.org/content/19/1/196lymph node (n = 41) and liver metastasis (n = 36). The
study protocol was approved by the institutional ethics
(Ethics Committee Erasme Hospital) and research review
boards. The belgian number (number of agreation) of this
committee is OM021. The reference for this study is
P2012/191. Consent has been established by the local
ethics committee and is in accordance with Belgian and
International law. For each patient, the following parame-
ters including age, TNM classification, tumour grade and
tumour size were performed according to the 4th edition
of WHO classification and are summarized in the Table 1.
Immunohistochemistry
The specimens were fixed in histology-grade 4% buffered
formalin. Series paraffin sections were stained with
haematoxylin and eosin and immunohistochemical de-
tection was performed according to the manufacturer’s
protocols (Table 2). We used a fully automated immuno-
histochemical system (Autostainer Link A48 Dako).
Semi-quantitative Assessment of Immunohistochemistry
We compared the distribution of CD34 and SMA be-
tween stromal areas located within the metastasis with
areas of normal liver and lymph node tissue. The im-
munoreactivity of CD34 and SMA was assessed semi-
quantitatively in the free tissue and the tumour. The
percentage of stromal cells expressing each antigen was
graded as “0”, “+”, “++”, “+++”, “++++” when up to 5%,
more than 5% and up to 25%, more than 25% and up to
50%, more than 50% and up to 75% or more than 75%
of stromal cells, disclosed immunoreactivity, respect-
ively. Percentages were assessed by two independent ob-
servers, assuming that a high-power microscopic field
(objective ×40, microscopic magnification: ×400) har-
boured 100 stromal cells (range: 75–150) as previously








Range 34 - 86 37 - 86
Primary tumour size
T1 (0.1- 2 cm) 18 21
T2 (>2- 5 cm) 14 17
T3 (>5 cm) 4 3
Primary tumour grade
Grade 1 3 8
Grade 2 23 22
Grade 3 10 11pattern of SMA and different clinical and histological
features (age, tumour size and grade, TNM classifica-
tion) was compared using a Chi-squared test. A p value
<0.05 was considered statistically significant. All analyses
were performed using Statistica®.
Results
CD 34 and SMA expression in lymph node metastases
In the normal lymph node, CD34 expression was limited
both on the capsule and pericapsular fibrocytes but also
in vessels within the parenchyma. CD34 fibrocytes were
totally absent in peritumoral stroma and the immunore-
activity was restricted to the vasculature. By contrast,
myofibroblasts were present in peritumoral stroma in
95% of cases with in a majority of cases more than 50%
of stromal cells positive but this expression was not sta-
tistically correlated with clinical or pathological features
(p > 0.05) (Tables 3 and 4). The peritumoral myofibro-
blasts surrounded intimately the malignant cells (Figure 1).
In the capsule both in the normal and peritumoral areas, a
strong immunoreactivity for SMA was also observed.
Lastly, in normal area, the reticular dendritic cells, stromal
cells with myoïd features and vascular walls showed as
previously described a discrete to moderate reactivity for
SMA [10-12].
CD 34 and SMA expression in liver metastases
In normal liver parenchyma, CD 34 expression was
limited to vascular walls and focal immunoreactivity in
portal tract. In the peritumoral stroma as in the lymph
node, the immunoreactivity was restricted to the vascu-
lature. Myofibroblasts are found intimately surrounding
tumoral metastatic cells in peritumoral stroma in 97% of
cases and like in lymph node was not statistically correlated
with clinical and pathological features (Tables 3 and 4)Table 3 Stromal SMA expression in lymph node and liver
metastatic sites
SMA expression 0 + or ++ +++ or ++++ Total
Lymph node 2 (5%) 5 (12%) 34 (83%) 41
Liver 1 (3%) 3 (8%) 32 (89%) 36















≤ 40 3 0 12 2
> 40 31 7 0.4 20 2 0.6
Tumour
grade
G1 6 2 2 1
G2 17 4 21 2
G3 11 1 0.6 9 1 0.9
Tumour
size (mm)
≤ 10 4 2 3 1
> 10 and
≤ 20
14 2 12 2
> 20 16 3 0.4 17 1 0.5
Figure 2 Myofibroblastic reaction within peritumoral stroma in
liver metastasis (x200).
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http://www.diagnosticpathology.org/content/19/1/196(Figure 2). In normal liver area, as previously described,
both hepatic stellate cells (Ito cells) in perisinusoidal
spaces, portal tracts and vascular walls were positive for
SMA [13].
Discussion
In preliminary papers, we have previously described that
the stromal reaction and in particular tumor-associated
myofibroblasts which are prominent in this stroma is a
common feature both in situ and invasive breast carcin-
omas. In the present study, for the first time, we have
demonstrated that myofibroblastic reaction was also
common both in lymph node and liver metastases.Figure 1 Typical example of SMA positive myofibroblasts
within lymph node metastasis of invasive mammary carcinoma
of NST (x100). Note that the myofibroblasts surround intimately the
cancer cells at high power view (inset; x400).Indeed, in more than 90% of metastatic lymph node and
liver metastatic cases, a peritumoral myofibroblastic re-
action is present and the myofibroblasts generally sur-
rounded intimately the tumoral cells. In addition, like in
primary breast carcinoma, we have not observed CD 34
fibrocytes in the stroma and the immunoreactivity for
this marker was restricted to the vascular walls, which
possibly represent “neovessels”.
In primary breast carcinoma, we have previously dem-
onstrated that one of the potential origin of this peritu-
moral myofibroblasts is the transformation of resident
fibrocytes CD 34 positive into myofibroblats by the way
of the TGF-ß 1/TGF-ß 1 receptor. However, the precursor
of these myofibroblasts remains hypothetical in metastatic
process.
In liver, we have could demonstrate like others, firstly
that myofibroblasts were absent in normal parenchyma
and secondly that SMA positivity was observed in vascular
walls, portal tract stroma and hepatic perisinusoidal cells
[13]. Therefore, as suggested by several authors in liver
fibrosis, these cells could be potential precursor for
myofibroblasts, which constitute the major source of
collagen deposits [14,15]. By analogy, in the lymph
node, stromal cells from the capsule, stromal cells with
myoïd features and endothelial cells are potential pre-
cursors of myofibroblasts. In addition, both in lymph node
and liver metastases, generation of myofibroblast either by
epithelial-mesenchymal transition (EMT) process from
epithelial carcinomatous cells, resident mesenchymal
stem cells, or from totipotential bone marrow cells is
still debate [16,17].
If the myofibroblastic reaction seems a constant event
both in breast carcinoma lymph node and liver metastases,
until now, it is unclear whether this event is favourable to
development of the metastatic process or by opposition is
just a secondary passive reaction remains unsettled. In
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http://www.diagnosticpathology.org/content/19/1/196diverse primary carcinomatous processes including
breast carcinoma, myofibroblasts promote tumour
growth, invasion and angiogenesis through the paracrine
effects of multiple factors including TGF-ß 1 and matrix-
metalloproteinases [18]. However, these factors are actually
poorly characterized in metastatic process actually.
Conclusions
In summary, the presence of activated myofibroblasts
in lymph node and liver metastases of breast carcinoma
highlights the importance of the microenvironment in
supporting cancers. Understanding the relationship between
myofibroblasts and metastases is not just of prognostic sig-
nificance, it could provide a new therapeutic target for the
treatment of advanced cancer.
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